Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 2,511 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer directly owned 41,967 shares in the company, valued at $4,467,806.82. This trade represents a 5.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $103.13 on Friday. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $130.23. The company has a market cap of $5.99 billion, a P/E ratio of -31.63 and a beta of 0.70. The business’s 50 day moving average is $112.94 and its two-hundred day moving average is $101.89. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm’s revenue was up 35.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.40) earnings per share. On average, equities analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on GKOS shares. BTIG Research restated a “buy” rating and issued a $131.00 price target on shares of Glaukos in a research report on Wednesday, February 18th. Wall Street Zen lowered shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Stifel Nicolaus increased their target price on shares of Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Wells Fargo & Company lifted their target price on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Finally, William Blair upgraded Glaukos to a “strong-buy” rating in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.69.

Institutional Investors Weigh In On Glaukos

A number of institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC increased its holdings in Glaukos by 183.4% in the 4th quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after buying an additional 1,953,578 shares during the period. Primecap Management Co. CA lifted its holdings in shares of Glaukos by 49.8% during the 4th quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after acquiring an additional 1,123,140 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Glaukos by 209.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after acquiring an additional 913,458 shares during the period. Norges Bank acquired a new stake in Glaukos during the second quarter valued at approximately $76,314,000. Finally, Millennium Management LLC lifted its position in shares of Glaukos by 75.3% during the 4th quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock worth $181,751,000 after buying an additional 691,289 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.